BioMarin Pharmaceutical I... (BMRN)
NASDAQ: BMRN
· Real-Time Price · USD
62.60
-1.09 (-1.71%)
At close: May 01, 2025, 12:08 PM
-1.71% (1D)
| Bid | 62.49 |
| Market Cap | 12B |
| Revenue (ttm) | 2.85B |
| Net Income (ttm) | 426.86M |
| EPS (ttm) | 2.21 |
| PE Ratio (ttm) | 28.33 |
| Forward PE | 15.42 |
| Analyst | Buy |
| Ask | 62.76 |
| Volume | 301,451 |
| Avg. Volume (20D) | 1,660,419 |
| Open | 63.20 |
| Previous Close | 63.69 |
| Day's Range | 62.24 - 63.58 |
| 52-Week Range | 52.93 - 94.85 |
| Beta | 0.30 |
About BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 26, 1999
Employees 3,040
Stock Exchange NASDAQ
Ticker Symbol BMRN
Website https://www.biomarin.com
Analyst Forecast
According to 21 analyst ratings, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is $90, which is an increase of 43.77% from the latest price.
Stock ForecastsNext Earnings Release
BioMarin Pharmaceutical Inc. is scheduled to release its earnings on May 1, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+4.76%
BioMarin Pharma shares are trading higher after th...
Unlock content with
Pro Subscription
2 months ago
+1.16%
BioMarin Pharma shares are trading higher after the company reported better-than-expected Q4 financial results.
